

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113282 A1

(51) International Patent Classification⁷: **C07C 317/46**,
323/56, A61P 5/48, A61K 31/192

S-SE-431 83 Molndal (SE). **HOLM, Patrik** [FI/SE];
AstraZeneca R & D Molndal, S-SE-431 83 Molndal (SE).

(21) International Application Number:
PCT/GB2004/002554

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
S-SE-151 85 Sodertalje (SE).

(22) International Filing Date: 16 June 2004 (16.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0314075.3 18 June 2003 (18.06.2003) GB

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GU, HN, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-SE-151 85 (SE).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LINDSTEDT-ALSTERMARK, Eva-Lotte** [SE/SE]; AstraZeneca R & D Molndal, S-SE-431 83 Molndal (SE). **BOLJE, Anna, Maria, Persdotter** [SE/SE]; AstraZeneca R & D Molndal,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC AGENTS

(57) Abstract: Substituted 3-phenylpropionic acid derivatives, processes for preparing such compounds, their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

WO 2004/113282 A1

THERAPEUTIC AGENTS

Field of the invention

The present invention relates to certain novel substituted 3-phenylpropionic acid derivatives, to processes for preparing such compounds, to their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Background of the invention


The metabolic syndrome including type 2 diabetes mellitus, refers to a cluster of manifestations including insulin resistance with accompanying hyperinsulinaemia, possibly type 2 diabetes mellitus, arterial hypertension, central (visceral) obesity, dyslipidaemia observed as deranged lipoprotein levels typically characterised by elevated VLDL (very low density lipoproteins), small dense LDL particles and reduced HDL (high density lipoprotein) concentrations and reduced fibrinolysis.

Recent epidemiological research has documented that individuals with insulin resistance run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering from myocardial infarction and stroke. In type 2 diabetes mellitus atherosclerosis related conditions cause up to 80% of all deaths.

In clinical medicine there is awareness of the need to increase the insulin sensitivity in patients with the metabolic syndrome and thus to correct the dyslipidaemia which is considered to cause the accelerated progress of atherosclerosis. However, currently this is not a universally accepted diagnosis with well-defined pharmacotherapeutic indications.

2-Phenylpropionic acids and cinnamic acids derivatives, unsubstituted in their acid chains, are disclosed in WO95/15752 and EP 544 488 as leukotriene antagonists and EP 947 500 discloses similar compounds which also have a sulphonamide or carboxamide group have prostaglandin E₂ modulating activity.

The S-enantiomer of the compound of formula C below



2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, is disclosed in PCT Publication Number WO99/62872. This compound is reported to be a modulator of peroxisome proliferator-activated receptors (PPAR, for a review of the PPARs see T.

M. Willson et al, J Med Chem 2000, Vol 43, 527) and has combined PPAR α /PPAR γ agonist activity (Structure, 2001, Vol 9, 699, P. Cronet et al). This compound is effective in treating conditions associated with insulin resistance. Other 2-phenylpropionic acid derivatives are disclosed in WO99/62870, WO99/62871 and WO01/40172. 2-Phenylpropanol derivatives having PPAR activity are disclosed in WO01/40170 and WO02/96863.

2-Chloro-2-((4-phenoxyalkyl)phenyl)propionic acids derivatives are disclosed as having hypolipidemic and hypoglycaemic properties in GB 1,496,156.

(S)- 2-Ethoxy-3-[4-(4-methylsulfonyloxyphenethylamino)phenyl]propionic acid is disclosed WO03/048116 which describes compounds that are predominantly PPAR alpha agonists.


2-Alkoxy-3-[(4-(2-quinolinylmethoxy)phenoxyalkyl)phenyl]propionic acid derivatives are described as having PPAR activity in WO01/66098.

WO00/64888 discloses diaryl acid derivatives as PPAR receptor ligands.

WO02/100813 discloses 2-alkoxy-3-{4-[(4-substitutedphenylphenoxy)-alkyl]phenyl}propionic acid compounds that have PPAR activity.

EP 1 216 980 discloses 2-alkoxy-3-{3-[(4-substitutedphenoxy)alkyl]phenyl}propionic acid compounds that have PPAR activity.

Co-pending PCT application No. PCT/GB02/05743 discloses compounds of formula I




wherein R¹ represents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin

resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Surprisingly a series of compounds has now been found which are PPAR α and /or PPAR γ modulators.


5 Description of the invention

The present invention provides a compound of formula I



and pharmaceutically acceptable salts thereof, in which

A is situated in the para position and represents A1 or A2 below



10 A1

A2

wherein

R is hydrogen;

-OR^a, wherein R^a represents hydrogen, alkyl, aryl or alkylaryl;

-NR^aR^b, wherein R^a and R^b are the same or different and R^a is as defined above and

15 R^b represents hydrogen, alkyl, aryl, alkylaryl, cyano, -OH, -Oalkyl, -Oaryl, -

Oalkylaryl, -COR^c or -SO₂R^d, wherein R^c represents hydrogen, alkyl, aryl or

alkylaryl and R^d represents alkyl, aryl or alkylaryl;

R¹ is alkyl, aryl, alkenyl, alkynyl, cyano;

-OR^e, wherein R^e is alkyl, acyl, aryl or alkylaryl;

20 -O-[CH₂]_m-OR^f, wherein R^f represents hydrogen, alkyl, acyl, aryl or alkylaryl and m represents an integer 1-8;

-OCONR^aR^c, wherein R^a and R^c are as defined above;

-SR^d, wherein R^d is as defined above;

-SOR^d, wherein R^d is as defined above;

-SO₂R^d, wherein R^d is as defined above;

-SO₂NR^aR^f, wherein R^f and R^a are as defined above;

5 -SO₂OR^a, wherein R^a is as defined above;

-COOR^d, wherein R^d is as defined above;

R² is hydrogen, alkyl, aryl, or alkylaryl,

R³ and R⁴ are the same or different and each represents hydrogen, alkyl, aryl, or alkylaryl,

n is an integer 1-6,

10 m is an integer 0 or 1;

D is situated in the ortho, meta or para position and represents alkyl, acyl, aryl, alkylaryl, halogen, -CN and NO₂, wherein the alkyl, aryl, or alkylaryl group is optionally substituted by R^b;

-NR^cCOOR^a, wherein R^c and R^a are as defined above;

15 -NR^cCOR^a, wherein R^c and R^a are as defined above;

-NR^cR^a, wherein R^c and R^a are as defined above;

-NR^cSO₂R^d, wherein R^c and R^d are as defined above;

-NR^cCONR^kR^c, wherein R^a, R^c and R^k are as defined above;

-NR^cCSNR^aR^k, wherein R^a, R^c and R^k are as defined above;

20 -OR^a, wherein R^a is as defined above;

-OSO₂R^d, wherein R^d is as defined above;

-SO₂R^d, wherein R^d is as defined above;

-SOR^d, wherein R^d is as defined above;

-SR^c, wherein R^c is as defined above;

25 -SO₂NR^aR^f, wherein R^f and R^a are as defined above;

-SO₂OR^a, wherein R^a is as defined above;

-CONR^cR^a, wherein R^c and R^a are as defined above;

-OCONR^fR^a, wherein R^f and R^a are as defined above;

D' is situated in the ortho, meta or para position and represents hydrogen, alkyl, acyl, aryl,

30 alkylaryl, halogen, -CN, -NO₂,

-NR^fR^b, wherein R^f and R^b are as defined above;

-OR^f, wherein R^f is as defined above;

-OSO₂R^d, wherein R^d is as defined above;

D'' is situated in the ortho, meta or para position and represents

hydrogen, alkyl, acyl, aryl, alkylaryl, halogen, -CN, -NO₂, -NR^fR^b wherein R^f and

R^b are as defined above;

-OR^f, wherein R^f is as defined above.

-OSO₂R^d, wherein R^d is as defined above

and T represents O, S or NR^t wherein R^t represents alkyl or alkylaryl provided that when A is A₁ and R², R³, and R⁴ each represent hydrogen and R¹ is OR^e wherein R^e is as previously

defined then T is not O;

wherein the term "aryl" denotes a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl group, or a fused ring system of any of these groups;

wherein the term "alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 6 carbon atoms or a substituted or unsubstituted cycloalkyl having

from 3 to 6 carbon atoms and wherein the term "substituted" denotes substitution by one or more alkyl, alkoxy, halogen, thiol, nitro, hydroxy, acyl, aryl or cyano groups or an amino group optionally substituted by one or two alkyl groups:

with a first proviso that when D is CH₃S(O)₂O and m is 1 and D' is H and T is O and n=2 and A is a group CH₂CH(SCH₂CH₂Ph)COR^x in which the phenyl is substituted in the 4


position by OH, Cl or F and in which R^x represents OH, or a protecting group for a carboxylic hydroxy group including a ethoxy or benzyloxy then D'' is not H;

and with a second proviso that when m is 1 and D is CH₃S(O)₂O and D' is H and T is O, S or NR and wherein R represents a H, a C₁₋₆alkyl group or a phenyl C₁₋₆alkyl group and n=2 and

A is a group CH₂CH(OC₂H₅)COR^x in which R^x represents OH, or a protecting group for a


carboxylic hydroxy group including a C₁₋₆alkoxy group or benzyloxy then D'' is not H.

The present invention provides a compound of formula I



and pharmaceutically acceptable salts thereof, in which

A is situated in the ortho, meta or para position and represents



R is hydrogen;

-OR^a, wherein R^a represents hydrogen, alkyl, aryl or alkylaryl;

5 -NR^aR^b, wherein R^a and R^b are the same or different and R^a is as defined above and

R^b represents hydrogen, alkyl, aryl, alkylaryl, cyano, -OH, -Oalkyl, -Oaryl, -

Oalkylaryl, -COR^c or -SO₂R^d, wherein R^c represents hydrogen, alkyl, aryl or

alkylaryl and R^d represents alkyl, aryl or alkylaryl;

R¹ is alkyl, aryl, alkenyl, alkynyl, cyano;

10 -OR^e, wherein R^e is alkyl, acyl, aryl or alkylaryl;

-O-[CH₂]_m-OR^f, wherein R^f represents hydrogen, alkyl, acyl, aryl or alkylaryl and m represents an integer 1-8;

-OCONR^aR^c, wherein R^a and R^c are as defined above;

-SR^d, wherein R^d is as defined above;

15 -SO₂NR^aR^f, wherein R^f and R^a are as defined above;

-SO₂OR^a, wherein R^a is as defined above;

-COOR^d, wherein R^d is as defined above;

R² is hydrogen, halogen, alkyl, aryl, or alkylaryl,

R³ and R⁴ are the same or different and each represents hydrogen, alkyl, aryl, or alkylaryl,

20 n is an integer 1-6,

m is an integer 0 or 1 (preferably m is 1);

D is situated in the ortho, meta or para position (preferably D is situated in the para position) and represents alkyl, acyl, aryl, alkylaryl, halogen, -CN and NO₂, wherein the alkyl, aryl, or alkylaryl group is optionally substituted by R^b;

25 -NR^cCOOR^a, wherein R^c and R^a are as defined above;

- NR^cCOR^a, wherein R^c and R^a are as defined above;
- NR^cR^a, wherein R^c and R^a are as defined above;
- NR^cSO₂R^d, wherein R^c and R^d are as defined above;
- NR^cCONR^kR^c, wherein R^a, R^c and R^k are as defined above;
- 5 -NR^cCSNR^aR^k, wherein R^a, R^c and R^k are as defined above;
- OR^a, wherein R^a is as defined above;
- OSO₂R^d, wherein R^d is as defined above;
- SO₂R^d, wherein R^d is as defined above;
- SOR^d, wherein R^d is as defined above;
- 10 -SR^c, wherein R^c is as defined above;
- SO₂NR^aR^f, wherein R^f and R^a are as defined above;
- SO₂OR^a, wherein R^a is as defined above;
- CONR^cR^a, wherein R^c and R^a are as defined above;
- OCONR^fR^a, wherein R^f and R^a are as defined above;
- 15 D' is situated in the ortho, meta or para position (preferably D' is situated in the ortho or meta position) and represents hydrogen, alkyl, acyl, aryl, alkylaryl, halogen, -CN, -NO₂,
 -NR^fR^b, wherein R^f and R^b are as defined above;
 -OR^f, wherein R^f is as defined above;
 -OSO₂R^d, wherein R^d is as defined above;
- 20 D'' is situated in the ortho, meta or para position and represents
 hydrogen, alkyl, acyl, aryl, alkylaryl, halogen, -CN, -NO₂, -NR^fR^b wherein R^f and R^b are as defined above;
 -OR^f, wherein R^f is as defined above.
 -OSO₂R^d, wherein R^d is as defined above
- 25 and T represents O, S or NR^t wherein R^t represents alkyl or alkylaryl;
 wherein the term "aryl" denotes a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl group, or a fused ring system of any of these groups;
 wherein the term "alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 6 carbon atoms or a substituted or unsubstituted cycloalkyl having
 30 from 3 to 6 carbon atoms and wherein the term "substituted" denotes substitution by one or more alkyl, alkoxy, halogen, thiol, nitro, hydroxy, acyl, aryl or cyano groups or an amino group optionally substituted by one or two alkyl groups:

with a first proviso that when D is $\text{CH}_3\text{S}(\text{O})_2\text{O}$ and D' is H and T is O and $n=2$ and A is a group $\text{CH}_2\text{CH}(\text{SCH}_2\text{CH}_2\text{Ph})\text{COR}^x$ in which the phenyl is substituted in the 4 position by OH, Cl or F and in which R^x represents OH, or a protecting group for a carboxylic hydroxy group including an ethoxy or benzyloxy then D'' is not H; and

- 5 a second proviso that when m is 1 and D is $\text{CH}_3\text{S}(\text{O})_2\text{O}$ and D' is H and T is O, S or NR and wherein R represents a H, a C_{1-6} alkyl group or a phenyl C_{1-6} alkyl group and $n=2$ and A is a group $\text{CH}_2\text{CH}(\text{OC}_2\text{H}_5)\text{COR}^x$ in which R^x represents OH, or a protecting group for a carboxylic hydroxy group including a C_{1-6} alkoxy group or benzyloxy then D'' is not H.

Preferably m is 1.

- 10 Preferably D is situated in the para position.

Preferably D' is situated in the ortho or meta position.

Further values of T, D and A in compounds of Formula I now follow. It will be understood that such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

- 15 In a first group of compounds of formula I, T is O.

In a second group of compounds of formula I, T is S.


In a third group of compounds of formula I T is NH.

- In a fourth group of compounds of formula I, A is a group $\text{CH}_2\text{CH}(\text{R}^y)\text{CO}_2\text{H}$ in which R^y represents aryethylthio in which the aryl is optionally substituted by one or more of the
20 following, C_{1-6} alkyl, C_{1-6} alkoxy, halo, cyano or an amino group optionally substituted by one or two alkyl groups.

In a fifth group of compounds of formula I, m is 1 and D is methanesulphonyloxy.

- In a sixth group of compounds of formula I, A represents a group of formula
 $\text{CH}_2\text{-CH}(\text{CO}_2\text{H})\text{-S}(\text{O})_p\text{-(CH}_2)_q\text{-Ar}$ wherein p is 0, 1 or 2; q is 1, 2, 3 or 4; and
25 Ar is phenyl or thienyl each of which is optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, cyano or an amino group optionally substituted by one or two alkyl groups.

In another aspect the present invention provides a compound of formula IA



IA

or a pharmaceutically acceptable salt thereof in which

D represents C_{1-6} alkylsulfonyloxy, aroyl, benzyl or a C_{1-6} alkyl group;

T represents O, S or NR^1 wherein R^1 represents alkyl or alkylaryl;

5 n is 1, 2 or 3;

p is 0, 1 or 2;

q is 1 or 2; and

Ar is phenyl or thienyl each of which is optionally substituted by hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halo, cyano or an amino group optionally substituted by one or two alkyl groups and

10 wherein the group containing the carboxylic acid group is attached to the phenyl ring meta or para to the group $(CH_2)_n-T$.

In a particular group of compounds of formula IA n is 2.

In a particular group of compounds of formula IA T is O.

In a particular group of compounds of formula IA D is CH_3SO_2O , particularly in the

15 para position to T

It will be appreciated by those skilled in the art the compounds of formula I contain an optically active centre and therefore can exist as enantiomers which can be separated as described later. It is expected that most, if not all, of the activity of the compounds of formula I resides in one enantiomer: either the S or the R enantiomer or the (+) or the (-) enantiomer.

20 The enantiomers which are more active in the assays which are described later are preferred forms of the present invention. It will be understood that the present invention includes all mixtures of this active enantiomer with the other enantiomer, for example the racemic mixture, which is a useful intermediate for the active enantiomer.

The active enantiomers may be isolated by separation of racemate for example by
25 fractional crystallization, resolution or HPLC on a chiral column (for example a ChiralpakTM AD 250x50 column). Alternatively the active enantiomers may be made by chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation with a chiral reagent.

The following definitions shall apply throughout the specification and the appended claims with regard to the group A.

Unless otherwise stated or indicated, the term "alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 6 carbon atoms or a cyclic alkyl having from 3 to 6 carbon atoms. The term "lower alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 3 carbon atoms or a cyclic alkyl having 3 carbon atoms. Examples of said alkyl and lower alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl as well as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.


Unless otherwise stated or indicated, the term "alkoxy" denotes a group O-alkyl, wherein alkyl is as defined above.

Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine, bromine or iodine.

Unless otherwise stated or indicated, the term "aryl" denotes a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl group, or a fused ring system of any of these groups, such as naphthyl. Preferably aryl is a substituted or unsubstituted phenyl.


Unless otherwise stated or indicated, the term "substituted" denotes an alkyl or an aryl group as defined above which is substituted by one or more alkyl, alkoxy, halogen, amino, thiol, nitro, hydroxy, acyl, aryl or cyano groups.

Unless otherwise stated or indicated, the term "alkylaryl" denotes a



wherein n is an integer 1 to 6 and R^i and R^j are the same or different and each represents hydrogen or an alkyl or aryl group as defined above.

Unless otherwise stated or indicated, the term "acyl" denotes a group



wherein R^j is hydrogen, alkyl, aryl and alkylaryl as defined above.

Unless otherwise stated or indicated, the terms "alkenyl" and "alkynyl" denote a straight or branched, substituted or unsubstituted unsaturated hydrocarbon group having one or more double or triple bonds and having a maximum of 6 carbon atoms, preferably 3 carbon atoms.

Unless otherwise stated or indicated the term "protective group" (R^P) denotes a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts. The protective group may also be a polymer resin such as Wang resin or 2-chlorotriyl chloride resin.

"Aroyl" means phenyl-(CO)-.

The term "prodrug" as used in this specification includes derivatives of the carboxylic acid group which are converted in a mammal, particularly a human, into the carboxylic acid group or a salt or conjugate thereof. The term "prodrug" also includes derivatives of the hydroxy substituent (when R^1 represents hydroxy) which are converted in a mammal, particularly a human, into the hydroxy group or a salt or conjugate thereof. It should be understood that, whilst not being bound by theory, it is believed that most of the activity associated with the prodrugs arises from the activity of the compound of formula I into which the prodrugs are converted. Prodrugs can be prepared by routine methodology well within the capabilities of someone skilled in the art. Various prodrugs of carboxy and hydroxy are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, 42: 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p.113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77:285 (1988); and
- e) N. Kakeya, *et al.*, Chem Pharm Bull, 32:692 (1984).

The above documents a to e are herein incorporated by reference.

In vivo cleavable esters are just one type of prodrug of the parent molecule. An *in vivo* hydrolysable (or cleavable) ester of a compound of the formula (I) that contains a carboxy or a hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically

acceptable esters for carboxy include C₁₋₆alkoxymethyl esters, for example, methoxymethyl; C₁₋₆alkanoyloxymethyl esters, for example, pivaloyloxymethyl; phthalidyl esters; C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters, for example, 1-cyclohexyl-carbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example, 5-methyl-1,3-

- 5 dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters, for example, 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention. An *in vivo* hydrolysable (or cleavable) ester of a compound of the formula (I) that contains a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a
- 10 result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxy carbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and
- 15 *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

The compounds of formula I have activity as medicaments, in particular the compounds of formula I are agonists of PPAR α and PPAR γ .

- 20 Specific compounds of the invention are one or more of the following:

2-[(4-cyanobenzyl)thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)-phenyl]propanoic acid;

2-({2-[4-(dimethylamino)phenyl]ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;

- 25 3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-2-({2-(2-thienyl)ethyl}thio)-propanoic acid;

2-({2-(2-fluorophenyl)ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]-propanoic acid;

2-({2-(3-methoxyphenyl)ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;

- 30 2-({2-(4-hydroxyphenyl)ethyl}sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;


- 3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-{[2-(4-hydroxyphenyl)ethyl]thio}propanoic acid;
- methyl 2-({2-[4-(benzyloxy)phenyl]ethyl}thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}-propanoate;
- 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoic acid;
- 2-[[2-(4-hydroxyphenyl)ethyl]thio]-3-[3-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;
- 3-{4-[2-(2-benzyl-4-methanesulfonyloxyphenoxy)ethyl]phenyl}-2-[2-(4-hydroxyphenyl)-ethylsulfanyl]propionic acid; and
- 2-[2-(4-tert-butoxy-phenyl)ethylsulfanyl]-3-{4-[2-(4-methanesulfonyloxyphenoxy)ethyl]-phenyl}propionic acid
- and pharmaceutically acceptable salts thereof.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms. Certain compounds of the present invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.

Methods of preparation


The compounds of the invention may be prepared as described in the Examples and analogous methods thereto known to persons skilled in the art. In particular methods disclosed in WO 99/62871 and analogous methods thereto may be used. However, the invention is not limited to these methods, the compounds may also be prepared as described for structurally related compounds in the prior art. The reactions can be carried out according to standard procedures or as described in the experimental section.

Compounds of formula I may be prepared by reacting a compound of formula II



II


in which D, m, D' and T are as previously defined with a compound of formula III



III


in which n, A and D'' are as previously defined and X is a leaving group for example halo or methanesulphonyloxy at a temperature in the range of 0-150°C optionally on the presence of an inert solvent. Optionally protection and deprotection steps known to those skilled in the art may be used as necessary.

Compounds of formula I in which T is O may be prepared by reacting a compound of formula IV



IV


in which D, m and D' are as previously defined with a compound of formula V



V

in which n, A and D'' are as previously defined using Mitsunobu conditions known to those skilled in the art for example in the presence of a coupling agent, for example cyanomethylenetri-N-butylphosphorane.

Compounds of formula IA may be prepared by reacting a compound of formula IB



IB

in which D, T, n, p, q and Ar are as previously defined and R^P represents a protecting group for a carboxylic hydroxy group as described in the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts, with a de-protecting agent. The protecting group may also be a resin, such as Wang resin or 2-chlorotriyl chloride resin.

5 Protecting groups may be removed in accordance to techniques which are well known to those skilled in the art. One such protecting group is where R^P represents a C_{1-6} alkoxy group for example methoxy or ethoxy or an arylalkoxy group eg benzyloxy, such that COR^4 represents an ester. Such esters can be reacted with a de-protecting agent e.g. a hydrolysing agent, for example lithium hydroxide in a mixture of THF and water, at a temperature in the
10 range of 0-100°C to give compounds of formula I.

Compounds of formula II, III, IV, and V may be prepared by methods known to those skilled in the art see for example WO 99/62871 herein incorporated by reference.

The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

15 Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual reactions may be performed at different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated
20 hereinbefore with a particular reaction).

The expression "inert solvent" refers to a solvent that does not react with the starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

Pharmaceutical preparations

25 The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient either as a free acid, or a pharmaceutical acceptable organic or inorganic base addition salt, in a pharmaceutically acceptable dosage
30 form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.0001-100 mg/kg body weight, preferably 0.001-10 mg/kg body weight.

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.5mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25mg, 50mg, 100mg and 250mg.

- 5 According to a further aspect of the invention there is thus provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

Pharmacological properties

- 10 The present compounds of formula (I) are useful for the prophylaxis and/or treatment of clinical conditions associated with inherent or induced reduced sensitivity to insulin (insulin resistance) and associated metabolic disorders (also known as metabolic syndrome). These clinical conditions will include, but will not be limited to, general obesity, abdominal obesity, arterial hypertension, hyperinsulinaemia, hyperglycaemia, type 2 diabetes and the
15 dyslipidaemia characteristically appearing with insulin resistance. This dyslipidaemia, also known as the atherogenic lipoprotein profile, is characterised by moderately elevated non-esterified fatty acids, elevated very low density lipoprotein (VLDL) triglyceride rich particles, high Apo B levels, low high density lipoprotein (HDL) levels associated with low apoAI particle levels and high Apo B levels in the presence of small, dense, low density lipoproteins
20 (LDL) particles, phenotype B.

The compounds of the present invention are expected to be useful in treating patients with combined or mixed hyperlipidemias or various degrees of hypertriglyceridemias and postprandial dyslipidemia with or without other manifestations of the metabolic syndrome.

- Treatment with the present compounds is expected to lower the cardiovascular
25 morbidity and mortality associated with atherosclerosis due to their antidyslipidaemic as well as antiinflammatory properties. The cardiovascular disease conditions include macro-angiopathies of various internal organs causing myocardial infarction, congestive heart failure, cerebrovascular disease and peripheral arterial insufficiency of the lower extremities. Because of their insulin sensitizing effect the compounds of formula I are also expected to
30 prevent or delay the development of type 2 diabetes from the metabolic syndrome and diabetes of pregnancy. Therefore the development of long-term complications associated with chronic hyperglycaemia in diabetes mellitus such as the micro-angiopathies causing renal disease, retinal damage and peripheral vascular disease of the lower limbs are expected to be

delayed. Furthermore the compounds may be useful in treatment of various conditions outside the cardiovascular system whether or not associated with insulin resistance, like polycystic ovarian syndrome, obesity, cancer and states of inflammatory disease including neurodegenerative disorders such as mild cognitive impairment, Alzheimer's disease,
5 Parkinson's disease and multiple sclerosis.

The compounds of the present invention are expected to be useful in controlling glucose levels in patients suffering from type 2 diabetes.

The present invention provides a method of treating or preventing dyslipidemias, the insulin resistance syndrome and/or metabolic disorders (as defined above) comprising the
10 administration of a compound of formula I to a mammal (particularly a human) in need thereof.

The present invention provides a method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.

15 In a further aspect the present invention provides the use of a compound of formula I as a medicament.

In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of insulin resistance and/or metabolic disorders.

20 Combination Therapy

The compounds of the invention may be combined with other therapeutic agents that are useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity. The compounds of the invention may be combined with another therapeutic agent that
25 decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

The compounds of the invention may be used alongside other therapies for the
30 treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors). An example of an alpha-

glucosidase inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt thereof, may be administered in association with a PPAR modulating agent.

5 PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma and/or delta agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, 10 WO 99/62871, WO 98/57941, WO 01/40170, WO 04/000790, WO 04/000295, WO 04/000294, WO 03/051822, WO 03/051821, WO 02/096863, WO 03/051826, WO 02/085844, WO 01/040172, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by 15 reference. Particularly a PPAR alpha and/or gamma and/or delta agonist refers to muraglitazar (BMS 298585), rivoglitazone (CS-011), netoglitazone (MCC-555), balaglitazone (DRF-2593, NN-2344), clofibrate, fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, pioglitazone, rosiglitazone, AVE-0847, AVE-8134, CLX-0921, DRF-10945, DRF-4832, LY-518674, LY-818, LY-929, 641597, GW-590735, GW-677954, GW-501516, MBX-102, ONO-5129, 20 KRP-101, R-483 (BM131258), TAK-559 or TAK-654. Particularly a PPAR alpha and/or gamma and/or delta agonist refers to tesaglitazar ((S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)phenyl]propanoic acid) and pharmaceutically acceptable salts thereof.

In addition the combination of the invention may be used in conjunction with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, 25 gliquidone, chloropropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolclamide and tolazamide. Preferably the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in 30 conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for

example the FDA and may be found in the Orange Book published by the FDA. Alternatively smaller doses may be used as a result of the benefits derived from the combination.

The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase inhibitor is a statin selected from the group consisting of atorvastatin, bervastatin, cerivastatin, dalvastatin, fluvastatin, itavastatin, lovastatin, mevastatin, nicostatin, nivastatin, pravastatin and simvastatin, or a pharmaceutically acceptable salt, especially sodium or calcium, or a solvate thereof, or a solvate of such a salt. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A particularly preferred statin is, however, a compound with the chemical name (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, [also known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-(methylsulfonyl)-amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, and its calcium and sodium salts are disclosed in European Patent Application, Publication No. EP-A-0521471, and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444. This latter statin is now known under its generic name rosuvastatin.

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.

The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor).

Suitable compounds possessing IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07449, WO 98/03818, WO 98/38182, WO 99/32478, WO 99/35135, WO 98/40375, WO 99/35153, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/47568, WO 00/61568, WO 00/62810, WO 01/68906, DE 19825804, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 01/68906, WO 01/66533, WO 02/32428, WO 02/50051, EP 864 582, EP489423, EP549967,

EP573848, EP624593, EP624594, EP624595 and EP624596 and the contents of these patent applications are incorporated herein by reference.

Particular classes of IBAT inhibitors suitable for use in the present invention are benzothiepinines, and the compounds described in the claims, particularly claim 1, of WO 00/01687, WO 96/08484 and WO 97/33882 are incorporated herein by reference. Other suitable classes of IBAT inhibitors are the 1,2-benzothiazepines, 1,4-benzothiazepines and 1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5-benzothiadiazepines.

One particular suitable compound possessing IBAT inhibitory activity is (3*R*,5*R*)-3-butyl-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl β -D-glucopyranosiduronic acid (EP 864 582). Other suitable IBAT inhibitors include one of:

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

a CETP (cholesterol ester transfer protein) inhibitor, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference;

a cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115 which are incorporated herein by reference;

a MTP (microsomal transfer protein) inhibitor for example those described in Science, 282, 751-54, 1998 which are incorporated herein by reference;

a nicotinic acid derivative, including slow release and combination products, for example, nicotinic acid (niacin), acipimox and niceritrol;

a phytosterol compound for example stanols;

probucol;

an anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB 2,184,122 and US 4,929,629);

an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha andrenergic

blocker, a beta andrenergic blocker, a mixed alpha/beta andrenergic blocker, an andrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic or a vasodilator; a CB1 antagonist or inverse agonist for example as described in WO01/70700 and EP 65635 ; a Melanin concentrating hormone (MCH) antagonist;

- 5 a PDK inhibitor; or
modulators of nuclear receptors for example LXR, FXR, RXR, and RORalpha;
or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

- 10 Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof, including active metabolites, which can be used in combination with a compound of formula I include but are not limited to, the following compounds: alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-
15 glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C,
20 pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril and zofenoprilat. Preferred ACE inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and
25 enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat.

- Preferred angiotensin II antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula I include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan,
30 valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred angiotensin II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.

Therefore in an additional feature of the invention, there is provided a method for for the treatment of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, 5 solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of 10 treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this combination section or a pharmaceutically acceptable 15 salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a 20 salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a 25 prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a first unit dosage form;
- 30 b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Examples

^1H NMR and ^{13}C NMR measurements were performed on a Varian Mercury 300 or Varian UNITY plus 400, 500 or 600 spectrometers, operating at ^1H frequencies of 300, 400,

500 and 600 MHz, respectively, and at ^{13}C frequencies of 75, 100, 125 and 150 MHz, respectively. Measurements were made on the delta scale (δ).

Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

5 Abbreviations

DMSO	dimethyl sulfoxide
EtOAc	ethyl acetate
DMF	<i>N,N</i> -dimethylformamide
THF	tetrahydrofuran
10 MeCN	acetonitrile
MeOH	methanol
TFA	trifluoroacetic acid
NH ₄ OAc	ammonium acetate
t	triplet
15 s	singlet
d	doublet
q	quartet
m	multiplet
bs	broad singlet

20 Starting Materials and Intermediates

Compound A. *S*-(4-Cyanobenzyl) ethanethioate

To a stirred solution of 4-(bromomethyl)benzonitrile (4.00 mmol, 784 mg) and thioacetic acid (4.20 mmol, 320 mg) in MeOH (8 mL) was added dropwise triethylamine (4.20 mmol, 425 mg). After cooling, the resulting solution was used in the next reaction step.

25 **Compound B. *S*-(2-[4-(Dimethylamino)phenyl]ethyl) ethanethioate**

2-[4-(Dimethylamino)phenyl]ethanol (4.00 mmol, 661 mg) and triethylamine (4.80 mmol, 486 mg) were dissolved in DCM (15 mL) and cooled in an ice-bath. Methanesulfonyl chloride (4.40 mmol, 504 mg) was added in portions and the ice-bath was removed. After 1.5 h water was added. The phases were separated. The organic phase was filtered through MgSO₄ and
30 evaporated to dryness. The crude mesylate was dissolved in MeOH (8 mL). To this solution was added triethylamine (4.20 mmol, 425 mg) and thioacetic acid (4.20 mmol, 320 mg). After cooling, the resulting solution was used in the next reaction step.

Compound C. *S*-(2-(2-Thienyl)ethyl) ethanethioate

A solution of the title compound was prepared from 2-(2-thienyl)ethyl methanesulfonate using the procedure described for compound A.

Compound D. S-[2-(2-fluorophenyl)ethyl] ethanethioate

A solution of the title compound was prepared from 2-(2-fluorophenyl)ethanol using the
5 procedure described for compound B.

Compound E. S-[2-(3-Methoxyphenyl)ethyl] ethanethioate

A solution of the title compound was prepared from 2-(3-methoxyphenyl)ethanol using the procedure described for compound B.

Compound F.

10 **Methyl 2-chloro-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate**

(i) Methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate

2-(4-Aminophenyl)ethanol (11g, 81mmol) and 32ml conc HCl was dissolved in acetone and cooled to 0°C. Sodium nitrite (5.6g, 81mmol) in 20ml water was added dropwise. The
15 temperature was kept under 0°C. After one hour, methyl acrylate (70g, 808mmol) and CuI (1.6g, 8mmol) were added (<0°C). The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and water was added. The water phase was extracted three times with EtOAc, the organic phases were pooled and washed with water, dried (MgSO₄) and evaporated under reduced pressure. The crude product was purified by flash
20 chromatography using a 65:35 mixture of EtOAc and heptane as eluent. Further purification by preparative HPLC (using a gradient of CH₃CN/ 5%CH₃CN-waterphase containing 0.1M NH₄OAc as eluent) gave 9.7g product (yield 49%) as an oil.

¹HNMR (400MHz, CDCl₃): 2.84 (t, 3H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.75 (s, 3H), 3.84 (t, 3H), 4.43 (t, 1H), 7.17 (d, 4H)

25 (ii) Methyl 3-(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate

Triphenylphosphine (2.4g, 9mmol) was added to a solution of methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate (2.1g, 8.5mmol) and 4-(benzyloxy)phenol (1.7g, 8mmol) in 20ml toluene under nitrogen atmosphere. The solution was warmed to 55°C and diisopropyl azodicarboxylate (1.8g, 9mmol) was added. The reaction mixture was stirred at 55°C
30 overnight. The mixture was allowed to cool and the solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography using a 80:20 mixture of heptane and EtOAc as eluent to yield 2.28g of the desired product (yield 61%) as colourless crystals.

¹HNMR (400MHz, CDCl₃): 3.05 (t, 2H), 3.16 (dd, 1H), 3.36 (dd, 1H), 3.75 (s, 3H), 4.12 (t, 2H), 4.45 (t, 1H), 5.01 (s, 2H), 6.82 (m, 2H), 6.90 (m, 2H), 7.13-7.27 (m, 4H), 7.29-7.47 (m, 5H).

(iii) Methyl 2-chloro-3-{4-[2-(4-hydroxyphenoxy)ethyl]phenyl}propanoate

- 5 Methyl 3-(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate (1.0g, 2.4mmol) and dimethyl sulfide (0.9g, 14mmol) was dissolved in 60ml CH₂Cl₂. Boron trifluoride etherate (2.0g, 14mmol) was added dropwise to the stirred solution. The reaction mixture was stirred for two days at room temperature. Another equivalent (0.4g, 2.87mmol) boron trifluoride etherate was added and the stirring was continued overnight.
- 10 Water was added. The phases were separated and the aqueous phase was extracted twice with CH₂Cl₂. The organic phases were pooled, washed (water, brine), dried (Na₂SO₄) and evaporated under reduced pressure. Further purification by preparative HPLC using a gradient of CH₃CN/ 5% CH₃CN-waterphase containing 0.1M NH₄OAc gave 0.55g of the desired product (yield 52%) as an oil.

- 15 ¹HNMR (400MHz, CDCl₃): 3.04 (t, 2H), 3.16 (dd, 1H), 3.35 (dd, 1H), 3.75 (s, 3H), 4.10 (t, 2H), 4.40 (t, 1H), 6.75 (m, 4H), 7.12-7.29 (m, 4H).

(iv) Methyl 2-chloro-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate

- Methyl 2-chloro-3-{4-[2-(4-hydroxyphenoxy)ethyl]phenyl}propanoate (334mg, 1.0mmol) and triethylamine (303mg, 3.0mmol) was dissolved in 20ml dichloromethane and cooled to -20°C under nitrogen atmosphere. Methanesulfonyl chloride (114mg, 1.0mmol) was added dropwise. The mixture was allowed to reach room temperature. After 2 hours dichloromethane was added, the mixture was washed (water, brine), dried (Na₂SO₄) and evaporated under reduced pressure to yield 394mg pure product (yield 96%).
- 20

- ¹HNMR (400MHz, CDCl₃): 3.02-3.11 (m, 5H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.74 (s, 3H), 4.14 (t, 2H), 4.44 (t, 1H), 5.29 (s, 2H), 6.88 (d, 2H), 7.14-7.25 (m, 6H).

Examples

Example 1

2-[(4-Cyanobenzyl)thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)-phenyl]propanoic acid

- 30 The reaction was performed under an argon atmosphere. To 0.80 mL of a stirred solution of compound A (0.40 mmol) in MeOH was added sodium methane thiolate (0.80 mmol, 56 mg) in MeOH (0.20 mL). After one hour of stirring, compound F (0.48 mmol, 200 mg) in MeCN was added. After 16 h of stirring, the mixture was evaporated to dryness using a vacuum

centrifuge. The residual crude product was dissolved in 0.5 M LiOH solution (THF/water 7:1, 0.50 mL) and stirred for 20 hours. After acidification with 12 M HCl (100 μ L) the stirring was continued for one hour. The crude product was filtered through a Teflon™ filter and purified using preparative HPLC (C8-column, gradient of 0.2 % TFA/MeCN) to give 24 mg of the title compound. ¹H-NMR (400 MHz, CDCl₃): 2.80-2.88 (m, 1H), 3.06 (t, J=6.9 Hz, 2H), 3.10 (s, 3H), 3.10-3.18 (m, 1H), 3.30 (t, J=7.7 Hz, 1H), 3.77-3.93 (m, 2H), 4.15 (t, J=6.9 Hz, 2H), 6.85-6.90 (m, 2H), 7.00-7.06 (m, 2H), 7.14-7.20 (m, 4H), 7.33-7.38 (m, 2H), 7.50-7.55 (m, 2H)

Example 2

10 2-((2-[4-(Dimethylamino)phenyl]ethyl)thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

The title compound (yield 6 mg) was prepared from compound B and F using the procedure described for example 1. ¹H-NMR (400 MHz, CDCl₃): 2.70-2.96 (m, 5H), 2.90 (s, 6H), 3.05 (t, J=7.0 Hz, 2H), 3.10 (s, 3H), 3.13-3.20 (m, 2H), 3.47-3.53 (m, 2H), 4.12 (t, J=7.0 Hz, 2H), 15 6.66-6.72 (m, 2H), 6.83-6.89 (m, 2H), 7.00-7.05 (m, 2H), 7.13-7.20 (m, 4H)

Example 3

3-[4-(2-{4-[(Methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-2-[[2-(2-thienyl)ethyl]thio]propanoic acid

The title compound (yield 3 mg) was prepared from compound C and F using the procedure 20 described for example 1. ¹H-NMR (400 MHz, CDCl₃): 2.85-3.00 (m, 4H), 3.02-3.13 (m, 6H), 3.15-3.22 (m, 1H), 3.50-3.56 (m, 1H), 4.13 (t, J=7.0 Hz, 2H), 6.77-6.80 (m, 1H), 6.84-6.87 (m, 2H), 6.87-6.92 (m, 1H), 7.10-7.13 (m, 1H), 7.15-7.19 (m, 6 H)

Example 4

25 2-[[2-(2-Fluorophenyl)ethyl]thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

The title compound (yield 2 mg) was prepared from compound D and F using the procedure described for example 1. ¹H-NMR (400 MHz, CDCl₃): 2.83-2.94 (m, 4H), 2.94-3.00 (m, 1H), 3.05 (t, J=7.1 Hz, 2H), 3.09 (s, 3H), 3.14-3.22 (m, 1H), 3.51-3.57 (m, 1H), 4.13 (t, J=7.1 Hz, 2H), 6.83-6.88 (m, 2H), 6.96-7.02 (m, 1H), 7.03-7.06 (m, 1H), 7.11-7.22 (m, 8 H)

30 Example 5

2-[[2-(3-Methoxyphenyl)ethyl]thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

The title compound (yield 16 mg) was prepared from compound B and F using the procedure described for example 1. ¹H-NMR (400 MHz, CDCl₃): 1.99-2.19 (m, 5H), 2.30 (t, J=6.9 Hz, 2H), 2.34 (s, 3H), 2.35-2.41 (m, 1H), 2.69-2.75 (m, 1H), 3.00 (s, 3H), 3.37 (t, J=6.9 Hz), 5.92-6.04 (m, 6 H), 6.37-6.48 (m, 4H), 6.52-6.58 (m, 2H)

5 **Example 6**

2-[[2-(4-Hydroxyphenyl)ethyl]sulfinyl]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid

a) 2-[4-(Benzyloxy)phenyl]ethanol

2-(4-Hydroxyphenyl) ethyl alcohol (30.5g, 0.22mol), benzyl bromide (39.6g, 0.23mol) and
10 potassium carbonate (33.5g, 0.24mol) were mixed and boiled under reflux for 4 hours. The reaction was left at room temperature for 12 hours. The solvent was evaporated and the residue was dissolved in water and chloroform. The phases were separated and the water phase was extracted one more time. The organic phases were pooled, dried (MgSO₄) and evaporated to give 47g of the desired product (93% yield).

15 b) 2-[4-(Benzyloxy)phenyl]ethyl methanesulfonate

2-[4-(Benzyloxy)phenyl]ethanol (22g, 96mmol), triethylamine (29g, 289mmol) and 200ml of dichloromethane were mixed and cooled to -20°C under a nitrogen atmosphere. Mesyl chloride (11g, 96mmol) was added dropwise. The reaction was stirred until it reached room temperature. The mixture was diluted with dichloromethane, washed twice with water,
20 dried (MgSO₄) and evaporated to give 31g of the desired product as brown crystals in quantitative yield.

¹HNMR (400MHz, CDCl₃): 2.82 (s, 3H), 2.98 (t, 2H), 4.37 (t, 2H), 5.05 (s, 2H), 6.91-6.96 (m, 2H), 7.12-7.17 (m, 2H), 7.28-7.46 (m, 5H).

c) S-{2-[4-(benzyloxy)phenyl]ethyl} ethanethioate

25 Cesium carbonate (33g, 101mmol) was added to a solution of thioacetic acid (8.47g, 111mmol) in 60ml methanol. After 30 minutes the solvent was evaporated and 160ml DMF was added. 2-[4-(Benzyloxy)phenyl]ethyl methanesulfonate (31g, 101mmol) was added drop wise. The mixture was stirred overnight at room temperature. Diethyl ether was added (~1liter). The organic phase was washed 5 times with water and once with brine, dried
30 (MgSO₄) and evaporated. The crude was further purified by flash chromatography using toluene as eluent to give 19g of the desired product (65% yield).

¹HNMR (400MHz, CDCl₃): 2.35 (s, 3H), 2.84 (t, 2H), 3.11 (t, 2H), 5.07 (s, 2H), 6.92-6.97 (m, 2H), 7.13-7.18 (m, 2H), 7.33-7.47 (m, 5H).

d) Methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate

4-Aminophenethyl alcohol (15g, 109mmol), 200ml acetone and 43ml hydrochloric acid were mixed and cooled on an ice bath. Sodium nitrite (7.5g, 109mmol) dissolved in 22ml water was added and the temperature was kept at -0°C . After 1h methyl acrylate (94.1g, 1093mmol) was added and then Cu(I) I (2.08g, 10.9mmol) in portions (still at 0°C). The reaction was stirred for $\sim 1.5\text{h}$ at 0°C and then overnight at room temperature. The acetone was evaporated and water was added. The water phase was extracted three times with ethyl acetate. The organic phase was washed with water, dried (MgSO_4) and evaporated. The crude product was filtered through a silica column (dichloromethane/methanol (99:1)). This crude product was put on another silica column using toluene/ethyl acetate (50:50) as eluent to give 19g of the desired product plus a by-product. Further purification on preparative HPLC using a gradient of CH_3CN / 10% CH_3CN -waterphase containing 0.1M ammoniumacetate, 20% CH_3CN to 100% CH_3CN in 50min, gave 12.7g pure product (46% yield) as a light yellow oil.

$^1\text{HNMR}$ (400MHz, CDCl_3): 2.84 (t, 2H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.75 (s, 3H), 3.84 (t, 2H), 4.43 (t, 1H), 7.15-7.18 (m, 4H).

e) Methyl 3-(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate

Methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate (12.2g, 50.6mmol) and 4-(benzyloxy)phenol (10.1g, 50.6mmol) was dissolved in 350ml dry toluene.

Triphenylphosphine (14.6g, 55.6mmol) was added. The mixture was heated to 55°C and diisopropyl azodicarboxylate (11.2g, 55.6mmol) was added. The reaction mixture was stirred overnight at 55°C . The reaction was followed on thin layer chromatography (heptane/ethyl acetate (80:20)). The solvent was evaporated and diethyl ether was added. The triphenylphosphine oxide was filtered off, the solvent was evaporated and the residue was purified by flash chromatography using toluene as eluent to yield 12.3g of the desired product (57% yield) as white crystals.

$^1\text{HNMR}$ (400MHz, CDCl_3): 3.05 (t, 2H), 3.16 (dd, 1H), 3.36 (dd, 1H), 3.75 (s, 3H), 4.11 (t, 2H), 4.45 (t, 1H), 5.02 (s, 2H), 6.80-6.84 (m, 2H), 6.88-6.91 (m, 2H), 7.14-7.28 (m, 4H), 7.29-7.44 (m, 5H).

f) Methyl 2-chloro-3-[4-[2-(4-hydroxyphenoxy)ethyl]phenyl]propanoate

Methyl 3-(4-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate (12.3g, 28.9mmol) and dimethyl sulfide (8.99g, 144.7mmol) were dissolved in 450ml dichloromethane. Boron trifluoride etherate (20.5g, 144.7mmol) was added dropwise. The

mixture was stirred for two days at room temperature. Water was added and the phases were separated. The water phase was extracted twice with dichloromethane. The organic phases were pooled and washed (water, brine), dried and evaporated. The crude product was further purified by flash chromatography using an 80:20 mixture of toluene/ethyl acetate as eluent to yield 8.9g (91% yield) of the desired product after freeze-drying.

¹HNMR (400MHz, CDCl₃): 3.04 (t, 2H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.75 (s, 3H), 4.10 (t, 2H), 4.45 (t, 1H), 6.72-6.79 (m, 4H), 7.15-7.28 (m, 4H).

g) Methyl 2-chloro-3-[4-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate

To a solution of methyl 2-chloro-3-[4-[2-(4-hydroxyphenoxy)ethyl]phenyl]propanoate (8.9g, 26.6mmol) and triethylamine (8.07g, 79.7mmol) in 250ml dichloromethane cooled to -20°C under nitrogen atmosphere was added methanesulfonyl chloride (3.05g, 26.6mmol) drop wise. The reaction was stirred until it reached room temperature.

Dichloromethane was added and the organic phase was washed twice with water and once with brine, dried (MgSO₄) and evaporated. The crude product was further purified by flash chromatography using a 99.5:0.5 mixture of dichloromethane/methanol as eluent to give 10.6g (97% yield) of the desired product.

¹HNMR (400MHz, CDCl₃): 3.07 (t, 2H), 3.09 (s, 3H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.74 (s, 3H), 4.14 (t, 2H), 4.44 (t, 1H), 6.87-6.89 (m, 2H), 7.16-7.25 (m, 6H).

h) Methyl 2-[(2-[4-(benzyloxy)phenyl]ethyl)thio]-3-[4-(2-[4-[(methylsulfonyl)oxy]-

phenoxy]ethyl)phenyl]propanoate

S-[2-[4-(benzyloxy)phenyl]ethyl] ethanethioate (6.70g, 23.4mmol) was dissolved in 43ml methanol under argon atmosphere. To this slurry was added sodium thiomethoxide (1.64g, 23.4mmol) dissolved in 22ml methanol. The reaction mixture was stirred for 30 minutes under an argon atmosphere. Half of the solvent volume was evaporated.

Methyl 2-chloro-3-[4-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate (9.65g, 23.4mmol) dissolved in 18ml dry DMF was added to the concentrated reaction mixture and stirred for 30min under an argon atmosphere. The solvent was evaporated and the residue was dissolved in ethyl acetate. The organic phase was extracted five times with water and once with brine, dried (MgSO₄) and evaporated. The crude product was further purified by flash chromatography using a 90:10 mixture of toluene/ethyl acetate as eluent to give 13.7g of the desired product (95% yield).

¹HNMR (400MHz, CDCl₃): 2.73-2.86 (m, 4H), 2.92 (dd, 1H), 3.06 (t, 2H), 3.09 (s, 3H), 3.18 (dd, 1H), 3.48-3.52 (m, 1H), 3.67 (s, 3H), 4.13 (t, 2H), 5.04 (s, 2H), 6.86-6.91 (m, 4H), 7.05-7.09 (m, 2H), 7.11-7.22 (m, 6H), 7.30-7.43 (m, 5H).

i) Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate

Methyl 2-([2-(4-(benzyloxy)phenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (13.79g, 22.2mmol) and dimethyl sulfide (6.90g, 111mmol) was dissolved in 320ml dichloromethane. Boron trifluoride etherate (15.76g, 111mmol) was added dropwise. The reaction was stirred at room temperature for 2 days. Water was added and the phases were separated. The water phase was washed twice with dichloromethane. The organic phases were pooled and washed (water, brine), dried (MgSO₄) and evaporated. The crude product was purified by flash chromatography using a 30:70 mixture of ethyl acetate/toluene as eluent to give 10.35g of the desired product (87% yield).

¹HNMR (400MHz, CDCl₃): 2.71-2.84 (m, 4H), 2.91 (dd, 1H), 3.06 (t, 2H), 3.10 (s, 3H), 3.17 (dd, 1H), 3.47-3.51 (m, 1H), 3.68 (s, 3H), 4.13 (t, 2H), 6.71-6.74 (m, 2H), 6.86-6.89 (m, 2H), 6.98-7.01 (m, 2H), 7.12-7.27 (m, 6H).

j) (+)-Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate and (-)-Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate

Preparative chiral chromatography of methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate Chiralpak AD (250 x 50 mm i.d.), 100% ethanol as mobile phase, flow rate 80 ml/min, UV-detection at 225 nm, ALP 670 nm. Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (1.01 g) was dissolved in pure ethanol (10 mg/ml), 50-100 mg was loaded on the column. The separation of the two enantiomers was partial and therefore a middle fraction between the peaks was collected. The middle fractions were continuously evaporated to a proper volume which was re-injected, however, with an unknown sample concentration. Injections were made every 25 minutes when the second enantiomer's peak maximum had been passed. The optical rotation was monitored on-line with an ALP-detector: E1 rotated counter-clockwise (-), and E2 rotated clockwise (+).

E1 : 462 mg (91%), ee>99%, [α]_D²⁰ -37 (c 1, MeOH)

E2 : 461 mg (91%), ee 97.1%, [α]_D²⁰ +35 (c 1, MeOH)

Analytical conditions: Chiralpak AD (4.6 x 250 mm), 100% ethanol, 0.5 ml/min, 225 nm.

k'_1 : 2.35, k'_2 : 3.27, α : 1.39.

^1H NMR (400MHz, CDCl_3): 2.71-2.83 (m, 4H), 2.91 (dd, 1H), 3.05 (t, 2H), 3.10 (s, 3H), 3.17 (dd, 1H), 3.46-3.50 (m, 1H), 3.67 (s, 3H), 4.13 (t, 2H), 6.70-6.74 (m, 2H), 6.85-6.89 (m, 2H),
5 6.97-7.01 (m, 2H), 7.11-7.20 (m, 6H).

k) Methyl (2R)-2-([2-(4-hydroxyphenyl)ethyl]sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate or Methyl (2S)-2-([2-(4-hydroxyphenyl)ethyl]sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate

Methyl (2S)-2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate or methyl (2R)-2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (188mg, 0.35mmol) was dissolved in 5ml dichloromethane and cooled on an ice bath. 3-Chloroperbenzoic acid (87mg, 0.35mmol) was added in portions. The mixture was stirred for 2h. 1M Na_2CO_3 was added. The phases were separated and the water phase was extracted twice with dichloromethane.
15 The organic phases were pooled and washed with 1M Na_2CO_3 -solution, dried (MgSO_4) and evaporated. The crude was further purified by preparative HPLC using a gradient of CH_3CN / 5% CH_3CN -waterphase containing 0.1M ammoniumacetate, 20% CH_3CN to 100% CH_3CN in 45 minutes to give 149mg product (77% yield) as a mixture of diastereomers/epimers.

^1H NMR (400MHz, CDCl_3) (diastereomers): 2.85-3.08 (m, 6H), 3.10 (s, 3H), 3.21-3.34 (m, 2H), 3.66, 3.73 (s,s 3H), 3.73-3.77, 3.80-3.85 (m,m, 1H), 4.13 (t, 2H), 6.74-6.78 (m, 2H), 6.85-6.89 (m, 2H), 7.01-7.06 (m, 2H), 7.12-7.22 (m, 6H).
20

l) 2-([2-(4-Hydroxyphenyl)ethyl]sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

Methyl (2R)-2-([2-(4-hydroxyphenyl)ethyl]sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate or methyl (2S)-2-([2-(4-hydroxyphenyl)ethyl]sulfinyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (149mg, 0.27mmol) was dissolved in THF (4ml) and cooled on an ice bath. Lithium hydroxide (0.7M, 1.36mmol) (aq) was added dropwise. The mixture was stirred overnight at room temperature. Water was added and the solvent (THF) was removed by evaporation. The remaining water phase was
25 acidified with 1M HCl and extracted twice with ethyl acetate. The organic phases were pooled and washed with brine, dried (MgSO_4) and evaporated. The crude product was further purified by preparative HPLC using a gradient of CH_3CN / 5% CH_3CN -waterphase containing
30

0.1M ammonium acetate, 20% CH₃CN to 100% CH₃CN in 30 minutes gave 89mg product (61%yield) as a racemate

¹HNMR (500MHz, CD₃OD): 2.90-3.32 (m, 11H), 3.84-3.91 (m, 1H), 4.17 (t, 2H), 6.70-6.75 (m, 2H), 6.92-6.95 (m, 2H), 7.04-7.09 (m, 2H), 7.18-7.26 (m, 6H).

5 **Example 7**

3-{4-[2-(4-Benzoylphenoxy)ethyl]phenyl}-2-[[2-(4-hydroxyphenyl)ethyl]thio]propanoic acid

a) 2-[4-(Benzyloxy)phenyl]ethanethiol

Sodium thiomethoxide(0.86g, 12.2mmol) was added to a solution of S-{2-[4-(benzyloxy)phenyl]ethyl} ethanethioate (See Example 6 c) (3.5g, 12.2mmol) in 60ml methanol. The mixture was stirred at room temperature for 30 minutes. 1M HCl was added and the water phase was extracted three times with dichloromethane. The organic phase was washed (brine), dried and evaporated to give 2.4g of the desired product (80% yield).
¹HNMR (300MHz, CDCl₃): 2.71-2.97 (m, 4H), 5.08 (s, 2H), 6.92-6.98 (m, 2H), 7.11-7.17 (m, 2H), 7.32-7.48 (m, 5H).

b) Methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate. See Example 6 step d.

c) Methyl 2-({2-[4-(benzyloxy)phenyl]ethyl}thio)-3-[4-(2-hydroxyethyl)phenyl]propanoate
Methyl 2-chloro-3-[4-(2-hydroxyethyl)phenyl]propanoate (2g, 8.24mmol), 2-[4-(benzyloxy)phenyl]ethanethiol (2.4g, 9.89mmol), potassium carbonate (1.4g, 9.89mmol) and 100ml DMF was stirred overnight at room temperature. The solvent was evaporated and the residue was dissolved in toluene. The organic phase was washed (water, brine), dried (MgSO₄) and evaporated. The crude was further purified by preparative hplc to give 1.55g of the desired product (40% yield) as yellow oil.

¹HNMR (600MHz, CDCl₃): 2.75-2.86 (m, 6H), 2.91 (dd, 1H), 3.17 (dd, 1H), 3.47-3.51 (m, 1H), 3.67 (s, 3H), 3.83 (t, 2H), 5.04 (s, 2H), 6.87-6.91 (m, 2H), 7.05-7.09 (m, 2H), 7.11-7.15 (m, 4H), 7.29-7.44 (m, 5H).

d) Methyl 3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-({2-[4-(benzyloxy)phenyl]ethyl}-thio)propanoate

Triphenylphosphine (120mg, 0.46mmol) was added to a solution of 4-benzoylphenol (82mg, 0.42mmol) and methyl 2-({2-[4-(benzyloxy)phenyl]ethyl}thio)-3-[4-(2-hydroxyethyl)-phenyl]propanoate (187mg, 0.42mmol) in 4ml toluene. The mixture was heated to 55°C and diisopropylazodicarboxylate (92mg, 0.46mmol) was added. The reaction was stirred at 55°C

for 24h. The solvent was evaporated and the crude residue was purified by preparative hplc to give 225mg of the desired product (83% yield).

¹HNMR (400MHz, CDCl₃): 2.75-2.90 (m, 4H), 2.96 (dd, 1H), 3.12 (t, 2H), 3.21 (dd, 1H), 3.51-3.57 (m, 1H), 3.70 (s, 3H), 4.25 (t, 2H), 5.06 (s, 2H), 6.89-6.99 (m, 4H), 7.07-7.13 (m, 2H), 7.15-7.19 (m, 2H), 7.22-7.26 (m, 2H), 7.31-7.53 (m, 7H), 7.55-7.61 (m, 1H), 7.74-7.86 (m, 4H).

e) Methyl 3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-([2-(4-hydroxyphenyl)ethyl]thio)-propanoate

Boron trifluoride etherate (128.3mg, 0.90mmol) was added dropwise to a solution of methyl 3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-([2-(4-benzoyloxy)phenyl]ethyl)thio)propanoate (114mg, 0.18mmol) and dimethyl sulfide (56.2mg, 0.90mmol) in 4ml dichloromethane. The reaction was stirred overnight at room temperature. Water was added and the phases were separated. The organic phase was washed (water, brine), dried (MgSO₄) and evaporated to give 78mg of the desired product (78% yield).

¹HNMR (500MHz, CDCl₃): 2.74-2.88 (m, 4H), 2.95 (dd, 1H), 3.13 (t, 2H), 3.22 (dd, 1H), 3.51-3.56 (m, 1H), 3.71 (s, 3H), 4.26 (t, 2H), 6.76-6.80 (m, 2H), 6.95-6.99 (m, 2H), 7.01-7.05 (m, 2H), 7.16-7.26 (m, 4H), 7.47-7.52 (m, 2H), 7.57-7.62 (m, 1H), 7.76-7.85 (m, 4H).

f) 3-{4-[2-(4-Benzoylphenoxy)ethyl]phenyl}-2-([2-(4-hydroxyphenyl)ethyl]thio)propanoic acid

Lithium hydroxide (6.9mg, 0.29mmol) dissolved in 0.5ml water was added dropwise to an ice-cooled solution of methyl 3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-([2-(4-hydroxyphenyl)ethyl]thio)propanoate (78mg, 0.14mmol) in 4ml THF. After 24h, water was added and the solvent was evaporated. The remaining water phase was acidified with 1M HCl and extracted three times with ethyl acetate. The organic phases were pooled and washed (water, brine), dried (Na₂SO₄) and evaporated. The crude product was further purified by preparative HPLC to give 40mg of the desired product (49% yield).

¹HNMR (400MHz, CDCl₃): 2.72-2.98 (m, 5H), 3.10 (t, 2H), 3.18 (dd, 1H), 3.47-3.53 (m, 1H), 4.25 (t, 2H), 6.71-6.76 (m, 2H), 6.87-6.94 (m, 2H), 6.97-7.04 (m, 2H), 7.14-7.23 (m, 4H), 7.44-7.51 (m, 2H), 7.54-7.60 (m, 1H), 7.74-7.81 (m, 4H).

Example 8**2-([2-(4-Hydroxyphenyl)ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoic acid****a) Methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoate**

Triphenylphosphine (157mg, 0.60mmol) was added to a solution of 2-n-propylphenol (74mg, 0.54mmol) and methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-[4-(2-hydroxyethyl)phenyl]propanoate (See Example 7 c) (245mg, 0.54mmol) in 6ml toluene. The mixture was heated to 55°C and diisopropylazodicarboxylate (121mg, 0.60mmol) was added. The reaction was stirred at 55°C for 24h. The solvent was evaporated and the crude residue was purified by preparative hplc to give 241mg of the desired product (77% yield).

¹HNMR (400MHz, CDCl₃): 0.96 (t, 3H), 1.52-1.61 (m, 2H), 2.57 (t, 2H), 2.76-2.90 (m, 4H), 2.95 (dd, 1H), 3.09 (t, 2H), 3.22 (dd, 1H), 3.52-3.57 (m, 1H), 3.70 (s, 3H), 4.17 (t, 2H), 5.07 (s, 2H), 6.79-6.96 (m, 4H), 7.08-7.18 (m, 6H), 7.22-7.29 (m, 2H), 7.33-7.49 (m, 5H).

b) Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoate

Boron trifluoride etherate (146mg, 1.03mmol) was added dropwise to a solution of methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoate (117mg, 0.21mmol) and dimethyl sulfide (63.9mg, 1.03mmol) in 4ml dichloromethane. The reaction was stirred overnight at room temperature. Water was added and the phases were separated. The organic phase was washed (water, brine), dried (MgSO₄) and evaporated. The crude product was further purified by preparative hplc to give 54mg of the desired product (54% yield).

¹HNMR (400MHz, CDCl₃): 0.95 (t, 3H), 1.50-1.61 (m, 2H), 2.57 (t, 2H), 2.75-2.87 (m, 4H), 2.94 (dd, 1H), 3.09 (t, 2H), 3.21 (dd, 1H), 3.50-3.57 (m, 1H), 3.69 (s, 3H), 4.17 (t, 2H), 6.73-6.77 (m, 2H), 6.79-6.91 (m, 2H), 6.99-7.05 (m, 2H), 7.11-7.18 (m, 4H), 7.21-7.26 (m, 2H).

c) 2-([2-(4-Hydroxyphenyl)ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoic acid

Lithium hydroxide (5mg, 0.20mmol) dissolved in 0.3ml water was added dropwise to an ice cooled solution of methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}propanoate (50mg, 0.10mmol) in 3ml THF. After 24h water was added and the solvent was evaporated. The remaining water phase was acidified with 1M HCl and extracted three times with ethyl acetate. The organic phases were pooled and washed

(water, brine) and dried (Na_2SO_4). The crude product was further purified by preparative HPLC to give 44mg of the desired product (87% yield).

^1H NMR (500MHz, CDCl_3): 0.94 (t, 3H), 1.51-1.60 (m, 2H), 2.57 (t, 2H), 2.72-2.98 (m, 5H), 3.08 (t, 2H), 3.20 (dd, 1H), 3.47-3.53 (m, 1H), 4.16 (t, 2H), 6.69-6.75 (m, 2H), 6.79-6.83 (m, 1H), 6.85-6.91 (m, 1H), 6.97-7.03 (m, 2H), 7.09-7.19 (m, 4H), 7.21-7.26 (m, 2H).

Example 9

2-[[2-(4-Hydroxyphenyl)ethyl]sulfonyl]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

a) Methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]sulfonyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate
 3-Chloroperbenzoic acid (198.6mg, 0.81mmol) was added to an ice cooled solution of methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (Example 6) (200mg, 0.32mmol) in 24ml dichloromethane. The reaction was stirred at room temperature for 2 hours. The mixture was washed with 1M NaHCO_3 and brine, dried (Na_2SO_4) and evaporated under reduced pressure to give 233mg of the desired product as a yellow oil (99%).

^1H NMR (500MHz, CDCl_3): 3.08 (t, 2H), 3.12 (s, 3H), 3.14-3.19 (m, 2H), 3.28-3.39 (m, 2H), 3.42-3.52 (m, 2H), 3.74 (s, 3H), 4.01-4.06 (m, 1H), 4.15 (t, 2H), 5.08 (s, 2H), 6.88-6.93 (m, 2H), 6.95-6.99 (m, 2H), 7.13-7.26 (m, 8H), 7.33-7.48 (m, 5H)

b) Methyl 2-([2-(4-hydroxyphenyl)ethyl]sulfonyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate
 Boron trifluoride etherate (130.5mg, 0.92mmol) was added dropwise during 5min to a solution of methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]sulfonyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (120mg, 0.18mmol) and dimethyl sulfide (57.1mg, 0.92mmol) in 5ml dichloromethane. The reaction was stirred overnight at room temperature. Water was added and the phases were separated. The organic phase was washed (water, brine), dried (MgSO_4) and evaporated. The crude product was further purified by preparative hplc to give 82mg of the desired product (71% yield).

^1H NMR (400MHz, CDCl_3): 3.03-3.16 (m, 7H), 3.22-3.47 (m, 4H), 3.74 (s, 3H), 3.99-4.05 (m, 1H), 4.14 (t, 2H), 6.76-6.81 (m, 2H), 6.87-6.91 (m, 2H), 7.06-7.25 (m, 8H).

c) 2-([2-(4-Hydroxyphenyl)ethyl]sulfonyl)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid

Lithium hydroxide (6.98mg, 0.29mmol) dissolved in 0.5ml water was added dropwise to an ice-cooled solution of methyl 2-[[2-(4-hydroxyphenyl)ethyl]sulfonyl]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoate (82mg, 0.145mmol) in 5ml THF.

After 48h water was added and the solvent was evaporated. The remaining water phase was acidified with 1M HCl and extracted three times with ethyl acetate. The organic phases were pooled and washed (water, brine) and dried (Na₂SO₄). The crude product was further purified by preparative HPLC to give 47mg of the desired product (54% yield).

¹HNMR (400MHz, (CD₃)₂CO): 3.02-3.08 (m, 4H), 3.21 (s, 3H), 3.34 (t, 2H), 3.41-3.60 (m, 2H), 4.21 (t, 2H), 4.23-4.27 (m, 1H), 6.77-6.81 (m, 2H), 6.98-7.01 (m, 2H), 7.12-7.16 (m, 2H), 7.23-7.28 (m, 6H).

Example 10

2-[[2-(4-Hydroxyphenyl)ethyl]thio]-3-[3-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)-phenyl]propanoic acid

a) 2-(3-aminophenyl)ethanol

3-Nitrophenethyl alcohol (4.8g, 28.7mmol) was dissolved in 117ml ethyl acetate. A small amount of 5% palladium on activated carbon was added. The reaction was stirred overnight at room temperature under hydrogen atmosphere. According to thin layer chromatography all the starting material was consumed. The mixture was filtered through Celite and the solvent was evaporated to give 3.7g (93% yield) of the desired product.

¹HNMR (400MHz, CDCl₃): 2.76 (t, 2H), 3.81 (t, 2H), 6.52-6.57 (m, 2H), 6.62 (d, 1H), 7.06-7.11 (m, 1H).

b) Methyl 2-chloro-3-[3-(2-hydroxyethyl)phenyl]propanoate

2-(3-aminophenyl)ethanol (3.01g, 21.9mmol), acetone (53ml) and conc. HCl (9ml) was mixed and cooled to 0°C. Sodium nitrite (1.86g, 21.9mmol) dissolved in 4ml water was added. The temperature was kept under 0°C. After 1h methyl acrylate (18.9g, 219.4mmol) was added and then Cu(I)I (0.42g, 2.19mmol) in portions. The mixture was stirred at room temperature over night. The acetone was evaporated and water was added. The water phase was extracted three times with ethyl acetate. The organic phases were pooled and washed (water, brine), dried (MgSO₄) and evaporated. The crude product was purified by flash chromatography using a 60:40 mixture of ethyl acetate/toluene as eluent to yield 2.95g of the desired product (yield 55%).

¹HNMR (400MHz, CDCl₃): 2.85 (t, 2H), 3.16 (dd, 1H), 3.35 (dd, 1H), 3.74 (s, 3H), 3.85 (t, 2H), 4.45 (t, 1H), 7.05-7.28 (m, 4H).

c) Methyl 3-(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate

To a solution of methyl 2-chloro-3-[3-(2-hydroxyethyl)phenyl]propanoate (2.95g, 12.2mmol) and 4-(benzyloxy)phenol (2.44g, 12.2mmol) in dry toluene (50ml) was added triphenylphosphine (3.51g, 13.4mmol). The mixture was heated to 55°C and

diisopropylazodicarboxylate (2.70g, 13.4mmol) was added. The reaction was stirred over night at 55°C under nitrogen atmosphere.

The solvent was evaporated under reduced pressure and the residual oil was purified by flash chromatography using toluene as eluent to give 2.66g of the desired product (51% yield).

¹HNMR (400MHz, CDCl₃): 3.05 (t, 2H), 3.15 (dd, 1H), 3.36 (dd, 1H), 3.72 (s, 3H), 4.11 (t, 2H), 4.44 (t, 1H), 5.01 (s, 2H), 6.80-6.84 (m, 2H), 6.87-6.91 (m, 2H), 7.06-7.20 (m, 4H), 7.23-7.43 (m, 5H).

d) Methyl 2-chloro-3-[3-{2-(4-hydroxyphenoxy)ethyl}phenyl]propanoate

Methyl 3-(3-{2-[4-(benzyloxy)phenoxy]ethyl}phenyl)-2-chloropropanoate (2.66g, 6.26mmol) and dimethyl sulfide (1.94g, 31.3mmol) was dissolved in dichloromethane (80ml). Boron

trifluoride diethyl etherate (4.44g, 31.3mmol) was added dropwise. The reaction mixture was stirred at room temperature for 36hours. Water was added, the phases were separated and the water phase was extracted twice with dichloromethane. The organic phases were pooled, washed with water and brine, dried (MgSO₄) and evaporated under reduced pressure to give 2.03g (96% yield) of the desired product.

¹HNMR (400MHz, CDCl₃): 3.04 (t, 2H), 3.15 (dd, 1H), 3.35 (dd, 1H), 3.73 (s, 3H), 4.10 (t, 2H), 4.45 (t, 1H), 6.72-6.79 (m, 4H), 7.07-7.27 (m, 4H).

e) Methyl 2-chloro-3-[3-{2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl}phenyl]propanoate

To a solution of methyl 2-chloro-3-[3-{2-(4-hydroxyphenoxy)ethyl}phenyl]propanoate (2.03g, 6.06mmol) in dichloromethane was added triethylamine (1.84g, 18.2mmol). The

mixture was cooled to -20°C under nitrogen atmosphere. Methanesulfonyl chloride (0.69g, 6.06mmol) was added dropwise. The mixture was stirred until it reached room temperature. Dichloromethane was added. The organic phase was washed twice with water, dried (MgSO₄) and evaporated. The crude product was purified by flash chromatography using a 99.5:0.5 mixture of dichloromethane/methanol as eluent to give 2.02g of the desired product (80% yield).

¹HNMR (400MHz, CDCl₃): 3.07 (t, 2H), 3.10 (s, 3H), 3.16 (dd, 1H), 3.36 (dd, 1H), 3.73 (s, 3H), 4.15 (t, 2H), 4.44 (t, 1H), 6.86-6.91 (m, 2H), 7.08-7.14 (m, 2H), 7.15-7.20 (m, 2H), 7.24-7.28 (m, 2H).

f) Methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate

S-[2-[4-(benzyloxy)phenyl]ethyl] ethanethioate (1.40g, 4.89mmol) and methanol (9ml) was added to a 2-necked round bottomed flask flushed with argon. To this slurry was added sodiumthiomethoxide (0.34g, 4.89mmol) dissolved in 5ml methanol. The mixture was stirred at room temperature for ~30min. Half the solvent volume was evaporated under reduced pressure. To the concentrated reaction mixture was added methyl 2-chloro-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate (2.02g, 4.89mmol) dissolved in 4.5ml dry DMF. The mixture was stirred at room temperature for ~30min under an argon atmosphere. The solvent was evaporated and the residue was dissolved in ethyl acetate. The organic phase was extracted five times with water and once with brine, dried (MgSO₄) and evaporated. The crude product (3g) was further purified by preparative HPLC using a gradient of CH₃CN/ 5% CH₃CN-waterphase containing 0.1M NH₄OAc, 40% CH₃CN => 100% CH₃CN in 50min, to give 2.56g (84% yield) of the desired product.

¹HNMR (400MHz, CDCl₃): 2.74-2.85 (m, 4H), 2.92 (dd, 1H), 3.05 (t, 2H), 3.08 (s, 3H), 3.18 (dd, 1H), 3.47-3.53 (m, 1H), 3.65 (s, 3H), 4.12 (t, 2H), 5.03 (s, 2H), 6.85-6.91 (m, 4H), 7.04-7.43 (m, 13H).

g) Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate

Methyl 2-([2-[4-(benzyloxy)phenyl]ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate (2.56g, 4.12mmol) and dimethyl sulfide (1.28g, 20.6mmol) was dissolved in dichloromethane (80ml). Boron trifluoride diethyl etherate (2.92g, 20.6mmol) was added drop wise. The reaction was stirred for 2 days at room temperature under nitrogen atmosphere. Water was added and the phases were separated. The water phase was extracted twice with dichloromethane. The organic phases were pooled and washed once with water, dried (MgSO₄) and evaporated to give 1.99g (91% yield) of the desired product.

¹HNMR (400MHz, CDCl₃): 2.70-2.84 (m, 4H), 2.92 (dd, 1H), 3.05 (t, 2H), 3.10 (s, 3H), 3.18 (dd, 1H), 3.45-3.50 (m, 1H), 3.66 (s, 3H), 4.12 (t, 2H), 6.70-6.73 (m, 2H), 6.85-6.89 (m, 2H), 6.97-7.00 (m, 2H), 7.03-7.10 (m, 2H), 7.12-7.25 (m, 4H).

h) 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoic acid

Methyl 2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy]ethyl)phenyl]propanoate (1.99g, 3.75mmol) was dissolved in THF(13.1ml) and cooled in an

ice-bath. Lithium hydroxide (0.45g, 18.75mmol) dissolved in 1.9ml water was added dropwise. The reaction was stirred at room temperature overnight. Water was added and the THF was evaporated. The remaining water phase was acidified with 1M HCl and extracted with ethyl acetate three times. The organic phases were pooled and washed with brine, dried (MgSO₄) and evaporated. The crude product was further purified by preparative HPLC using a gradient of CH₃CN/ 5% CH₃CN-water phase containing 0.1M NH₄OAc, 20% CH₃CN=> 100% CH₃CN in 40 minutes, to give 1.4g of the desired product (76% yield).
1H NMR (400MHz, CD₃OD): 2.67-2.88 (m, 5H), 3.03 (t, 2H), 3.11 (dd, 1H), 3.13 (s, 3H), 3.42-3.47 (m, 1H), 4.16 (t, 2H), 6.65-6.68 (m, 2H), 6.90-6.97 (m, 4H), 7.05-7.09 (m, 1H), 7.12-7.22 (m, 5H).

Example 11

3-{4-[2-(2-benzyl-4-methanesulfonyloxyphenoxy)ethyl]phenyl}-2-[2-(4-hydroxyphenyl)ethylsulfanyl]-propionic acid

Lithium hydroxide (62 mg, 2.58 mmol) in water (7.5 ml) was added to a stirred solution of 3-{4-[2-(2-benzyl-4-methanesulfonyloxyphenoxy)ethyl]phenyl}-2-[2-(4-hydroxyphenyl)ethylsulfanyl]-propionic acid methyl ester (234 mg, 0.377 mmol, prepared by analogous methods to the previous examples) in THF (15 ml) at room temperature. After 16 h 2M Potassium hydrogensulfate solution (5 ml, 10 mmol) was added and the THF was removed under reduced pressure. Dilution with water and extraction with methylene chloride, drying of the organic phase (magnesium sulfate) and evaporation of the solvent gave a residue which was purified by preparative HPLC (acetonitrile/ammonium acetate buffer) to give 3-{4-[2-(2-benzyl-4-methanesulfonyloxyphenoxy)ethyl]phenyl}-2-[2-(4-hydroxyphenyl)ethylsulfanyl]-propionic acid. Yield 66 mg (29%).

NMR (CDCl₃, 500 MHz) δ 7.31-7.08 (m, 9), 7.06-7.03 (m, 1), 6.95 (d, 1), 6.83 (d, 2), 6.71 (d, 1), 6.65 (d, 2), 4.04 (t, 2), 3.89 (s, 2), 3.50 ("t", 1), 3.19-3.10 (m, 1), 3.01 (s, 3), 2.99-2.94 (t, 2), 2.91-2.83 (m, 1), 2.80-2.58 (m, 4).

Example 12

2-[2-(4-tert-Butoxy-phenyl)-ethylsulfanyl]-3-{4-[2-(4-methanesulfonyloxyphenoxy)ethyl]-phenyl}propionic acid

2-[2-(4-tert-Butoxy-phenyl)-ethylsulfanyl]-3-{4-[2-(4-methanesulfonyloxyphenoxy)ethyl]-phenyl}propionic acid methyl ester (51 mg, 0.087 mmol, prepared by analogous methods to the previous examples) was stirred overnight with lithium hydroxide (3 mg, 0.13 mmol) in THF (0.5 ml) and water (0.1 ml). Water was added and THF was removed in vacuo. The

mixture was washed with diethyl ether and the aqueous phase was acidified with potassium hydrogensulfate and then extracted with methylene chloride. Preparative HPLC (acetonitrile/ammonium acetate buffer) yielded 2-[2-(4-tert-butoxy-phenyl)-ethylsulfanyl]-3-{4-[2-(4-methanesulfonyloxyphenoxy)ethyl]-phenyl}propionic acid (16 mg, 32%). NMR (CDCl₃, 500 MHz) δ 7.20-7.15 (m, 6), 7.04 (d, 2), 6.88 (dd, 4), 4.13 (t, 2), 3.51 (t, 1), 3.22-3.14 (m, 1), 3.10 (s, 3), 3.05 (t, 2), 2.96-2.73 (m, 5), 1.33 (s, 9).

Biological activity


The compounds of the invention were tested in the assays described in WO03/051821 which is incorporated herein by reference. For example the EC₅₀ of Example 7 for human PPAR alpha is 0.78 μ mol/l

The compounds of formula I have an affinity for PPAR α and / or PPAR γ . The compounds of formula I are selected because of their superior potency *in vitro* and/or higher affinity and /or higher *in vivo* efficacy. The compounds also have a better selectivity profile, which is expected to improve *in vivo* safety.

In addition the compounds of the present invention may have improved DMPK (Drug Metabolism and Pharmacokinetic) properties, for example improved metabolic stability *in vitro* or bioavailability. The compounds also have an improved solubility and/or a promising toxicological profile.


CLAIMS

1. A compound of formula I



and pharmaceutically acceptable salts thereof, in which

A is situated in the para position and represents A1 or A2 below



wherein

- 10 R is hydrogen;

-OR^a, wherein R^a represents hydrogen, alkyl, aryl or alkylaryl;

-NR^aR^b, wherein R^a and R^b are the same or different and R^a is as defined above and R^b represents hydrogen, alkyl, aryl, alkylaryl, cyano, -OH, -Oalkyl, -Oaryl, -

Oalkylaryl, -COR^c or -SO₂R^d, wherein R^c represents hydrogen, alkyl, aryl or

- 15 alkylaryl and R^d represents alkyl, aryl or alkylaryl;

R¹ is alkyl, aryl, alkenyl, alkynyl, cyano;

-OR^e, wherein R^e is alkyl, acyl, aryl or alkylaryl;

-O-[CH₂]_m-OR^f, wherein R^f represents hydrogen, alkyl, acyl, aryl or alkylaryl and m represents an integer 1-8;

- 20 -OCONR^aR^c, wherein R^a and R^c are as defined above;

-SR^d, wherein R^d is as defined above;

-SOR^d, wherein R^d is as defined above;

-SO₂R^d, wherein R^d is as defined above;

-SO₂NR^aR^f, wherein R^f and R^a are as defined above;

-SO₂OR^a, wherein R^a is as defined above;

-COOR^d, wherein R^d is as defined above;

5 R² is hydrogen, alkyl, aryl, or alkylaryl,

R³ and R⁴ are the same or different and each represents hydrogen, alkyl, aryl, or alkylaryl,

n is an integer 1-6,

m is an integer 0 or 1;

D is situated in the ortho, meta or para position and represents alkyl, acyl, aryl, alkylaryl,

10 halogen, -CN and NO₂, wherein the alkyl, aryl, or alkylaryl group is optionally substituted by R^b;

-NR^cCOOR^a, wherein R^c and R^a are as defined above;

-NR^cCOR^a, wherein R^c and R^a are as defined above;

-NR^cR^a, wherein R^c and R^a are as defined above;

15 -NR^cSO₂R^d, wherein R^c and R^d are as defined above;

-NR^cCONR^kR^c, wherein R^a, R^c and R^k are as defined above;

-NR^cCSNR^aR^k, wherein R^a, R^c and R^k are as defined above;

-OR^a, wherein R^a is as defined above;

-OSO₂R^d, wherein R^d is as defined above;

20 -SO₂R^d, wherein R^d is as defined above;

-SOR^d, wherein R^d is as defined above;

-SR^c, wherein R^c is as defined above;

-SO₂NR^aR^f, wherein R^f and R^a are as defined above;

-SO₂OR^a, wherein R^a is as defined above;

25 -CONR^cR^a, wherein R^c and R^a are as defined above;

-OCONR^fR^a, wherein R^f and R^a are as defined above;

D¹ is situated in the ortho, meta or para position and represents hydrogen, alkyl, acyl, aryl, alkylaryl, halogen, -CN, -NO₂,

-NR^fR^b, wherein R^f and R^b are as defined above;

30 -OR^f, wherein R^f is as defined above;

-OSO₂R^d, wherein R^d is as defined above;

D'' is situated in the ortho, meta or para position and represents

hydrogen, alkyl, acyl, aryl, alkylaryl, halogen, -CN, -NO₂, -NR^fR^b wherein R^f and R^b are as defined above;

-OR^f, wherein R^f is as defined above.

5 -OSO₂R^d, wherein R^d is as defined above

and T represents O, S or NR¹ wherein R¹ represents alkyl or alkylaryl provided that when A is A1 and R², R³, and R⁴ each represent hydrogen and R¹ is OR^e wherein R^e is as previously defined then T is not O;

wherein the term "aryl" denotes a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl

10 group, or a fused ring system of any of these groups;

wherein the term "alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 6 carbon atoms or a substituted or unsubstituted cycloalkyl having from 3 to 6 carbon atoms and wherein the term "substituted" denotes substitution by one or more alkyl, alkoxy, halogen, thiol, nitro, hydroxy, acyl, aryl or cyano groups or an amino

15 group optionally substituted by one or two alkyl groups:


with a first proviso that when D is CH₃S(O)₂O and m is 1 and D' is H and T is O and n=2 and A is a group CH₂CH(SCH₂CH₂Ph)COR^x in which the phenyl is substituted in the 4 position by OH, Cl or F and in which R^x represents OH, or a protecting group for a carboxylic hydroxy group including a ethoxy or benzyloxy then D'' is not H;

20 and with a second proviso that when m is 1 and D is CH₃S(O)₂O and D' is H and T is O, S or NR and wherein R represents a H, a C₁₋₆alkyl group or a phenyl C₁₋₆alkyl group and n=2 and A is a group CH₂CH(OC₂H₅)COR^x in which R^x represents OH, or a protecting group for a carboxylic hydroxy group including a C₁₋₆alkoxy group or benzyloxy then D'' is not H.

25 2. A compound of formula I as claimed in claim 1 in which A represents a group of formula -CH₂-CH(CO₂H)-S(O)_p-(CH₂)_q-Ar wherein p is 0, 1 or 2; q is 1, 2, 3 or 4; and Ar is phenyl or thienyl each of which is optionally substituted by one or more hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, cyano or an amino group optionally substituted by one or two alkyl groups.

30

3. A compound of formula I as claimed in claim 1 represented by formula IA



IA

or a pharmaceutically acceptable salt thereof in which

D represents C_{1-6} alkylsulfonyloxy, aroyl, or a C_{1-6} alkyl group;

T represents O, S or NR^t wherein R^t represents alkyl or alkylaryl;

n is 1, 2 or 3;

p is 0, 1 or 2;

q is 1 or 2; and

Ar is phenyl or thienyl each of which is optionally substituted by hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, halogen, cyano or an amino group optionally substituted by one or two alkyl groups

and wherein the group containing the carboxylic acid group is attached to the phenyl ring meta or para to the group $(CH_2)_n-T$.

4. A compound selected from one or more of the following:

2-[(4-cyanobenzyl)thio]-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)-phenyl]propanoic

acid;

2-({2-[4-(dimethylamino)phenyl]ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;

3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-2-({2-(2-thienyl)ethyl}thio)-propanoic acid;

2-({2-(2-fluorophenyl)ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]-propanoic acid;

2-({2-(3-methoxyphenyl)ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;

2-({2-(4-hydroxyphenyl)ethyl}thio)-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}-ethyl)phenyl]propanoic acid;


3-{4-[2-(4-benzoylphenoxy)ethyl]phenyl}-2-({2-(4-hydroxyphenyl)ethyl}thio)propanoic acid;

methyl 2-({2-[4-(benzyloxy)phenyl]ethyl}thio)-3-{4-[2-(2-propylphenoxy)ethyl]phenyl}-propanoate;

2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[4-[2-(2-propylphenoxy)ethyl]phenyl]propanoic acid;
2-([2-(4-hydroxyphenyl)ethyl]thio)-3-[3-(2-[4-[(methylsulfonyl)oxy]phenoxy)-
ethyl]phenyl]propanoic acid;
3-[4-[2-(2-benzyl-4-methanesulfonyloxyphenoxy)ethyl]phenyl]-2-[2-(4-hydroxyphenyl)-
5 ethylsulfanyl]propionic acid; and
2-[2-(4-tert-butoxy-phenyl)ethylsulfanyl]-3-[4-[2-(4-methanesulfonyloxyphenoxy)ethyl]-
phenyl]propionic acid
and pharmaceutically acceptable salts thereof.


- 10 5. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 4 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
6. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 4 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.
- 15 7. A method of treating or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to any one of claims 1 to 4 to a mammal in need thereof.
- 20 8. The use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of lipid disorders (dyslipidemia) whether or not associated with insulin resistance.
9. A method of treating or preventing type 2 diabetes comprising the administration of an
25 effective amount of a compound of formula I according to any one of claims 1 to 4 to a mammal in need thereof.
10. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with another therapeutic agent that is useful in the treatment of
30 disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity.

11. A process for preparing a compound of formula I as claimed in claim 1 by reacting a compound of formula II



II


in which D, m, D' and T are as previously defined with a compound of formula III



III

in which n, A and D'' are as previously defined and X is a leaving group for example halo or methanesulphonyloxy at a temperature in the range of 0-150°C optionally in the presence of an inert solvent.

12. A process to prepare a compounds of formula IA as claimed in claim3 by reacting a compound of formula IB



IB

in which D, T, n, p, q and Ar are as previously defined and R^P represents a protecting group for a carboxylic hydroxy group with a de-protecting agent.

INTERNATIONAL SEARCH REPORT

ional Application No

GB2004/002554

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C317/46 C07C323/56 A61P5/48 A61K31/192

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03/051826 A (ASTRAZENECA UK LTD ; BOIJE ANNA MARIA PERSDOTTER (SE); HOLM PATRIK (SE) 26 June 2003 (2003-06-26) cited in the application the whole document	1-12
X	GB 1 496 156 A (TAKEDA CHEMICAL INDUSTRIES LTD) 30 December 1977 (1977-12-30) cited in the application the whole document	1-12
X	WO 03/048116 A (MADHAVAN GURRAM RANGA ; VIKRAMADITHYAN REEBA KANNIMEL (IN); IQBAL JAVE) 12 June 2003 (2003-06-12) cited in the application the whole document	1-12
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

21 October 2004

Date of mailing of the international search report

03/11/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bertrand, F

INTERNATIONAL SEARCH REPORT

onal Application No

GB2004/002554

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/62871 A (BOIJE MARIA ; INGHARDT TORD (SE); ANDERSSON KJELL (SE); ASTRA AB (SE);) 9 December 1999 (1999-12-09) cited in the application the whole document	1-12
X	WO 02/100813 A (GONZALES GARCIA MARIA ROSARIO ; MARTIN JOSE ALFREDO (ES); ROJO ISABEL) 19 December 2002 (2002-12-19) cited in the application claims; example 127	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002554

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03051826	A	26-06-2003	CA 2470066 A1 EP 1458677 A1 WO 03051826 A1	26-06-2003 22-09-2004 26-06-2003
GB 1496156	A	30-12-1977	JP 1150848 C JP 50140414 A JP 57042052 B JP 51043738 A AT 341505 B AT 988174 A AU 7601874 A BE 823172 A1 DE 2458375 A1 DK 644374 A ES 432790 A1 FI 357974 A FR 2254549 A1 HU 170228 B NL 7416220 A NO 744352 A US 4074057 A SE 7415540 A	14-06-1983 11-11-1975 07-09-1982 14-04-1976 10-02-1978 15-06-1977 03-06-1976 10-06-1975 19-06-1975 18-08-1975 16-02-1977 13-06-1975 11-07-1975 28-04-1977 16-06-1975 07-07-1975 14-02-1978 13-06-1975
WO 03048116	A	12-06-2003	CA 2469227 A1 EP 1453795 A2 WO 03048116 A2 US 2003229083 A1	12-06-2003 08-09-2004 12-06-2003 11-12-2003
WO 9962871	A	09-12-1999	AT 261429 T AT 251130 T AU 4667099 A AU 752262 B2 AU 4667299 A BR 9910913 A BR 9910921 A CA 2334107 A1 CA 2334374 A1 CN 1312795 T CN 1311769 T DE 69911770 D1 DE 69911770 T2 DE 69915470 D1 DK 1084101 T3 DK 1084102 T3 EE 200000717 A EE 200000725 A EP 1084101 A1 EP 1084102 A1 ES 2209457 T3 HK 1034957 A1 HU 0103226 A2 ID 28164 A ID 29457 A JP 2002516898 T JP 2002516899 T NO 20006114 A NO 20006116 A NZ 508453 A	15-03-2004 15-10-2003 20-12-1999 12-09-2002 20-12-1999 06-03-2001 06-03-2001 09-12-1999 09-12-1999 12-09-2001 05-09-2001 06-11-2003 19-08-2004 15-04-2004 14-06-2004 02-02-2004 15-08-2001 17-06-2002 21-03-2001 21-03-2001 16-06-2004 30-04-2004 28-01-2002 10-05-2001 30-08-2001 11-06-2002 11-06-2002 02-02-2001 02-02-2001 30-06-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/002554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9962871 A		PL 344681 A1	19-11-2001
		PL 344682 A1	19-11-2001
		PT 1084101 T	30-07-2004
		PT 1084102 T	27-02-2004
		WO 9962870 A1	09-12-1999
		WO 9962871 A1	09-12-1999
		SI 1084102 T1	29-02-2004
		SI 1084101 T1	31-08-2004
		SK 17672000 A3	06-08-2001
		SK 17692000 A3	10-05-2001
		TR 200003543 T2	20-04-2001
		TR 200003583 T2	21-05-2001
		TW 446694 B	21-07-2001
		TW 548263 B	21-08-2003
		US 6630600 B1	07-10-2003
		US 6362360 B1	26-03-2002
		ZA 200006771 A	20-05-2002
WO 02100813 A	19-12-2002	BR 0210190 A	06-04-2004
		CA 2449256 A1	19-12-2002
		CZ 20033309 A3	12-05-2004
		EE 200400001 A	16-02-2004
		EP 1392637 A2	03-03-2004
		HR 20031001 A2	30-06-2004
		SK 14912003 A3	08-09-2004
		WO 02100813 A2	19-12-2002